À̹ÌÁö È®´ë South Korea¡¯s biosimilar manufacturer Samsung Biologics Co. will open a contract development organization (CDO) research and development center in San Francisco, the United States, on Thursday.
The R&D center will serve as a base for the company¡¯s global CDO business. It will expand its global network beyond San Francisco to Boston, the center of the U.S. biotechnology industry, and Europe.
The CDO business develops experimental drugs for clinical tests as well as designs manufacturing process for mass production of new drugs on a contract basis. The world¡¯s top contract manufacturing organization (CMO) has been aggressively expanding the CDO and contract research organization (CRO).
By Kim Si-kyun and Choi Mira
[¨Ï Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]